168 related articles for article (PubMed ID: 19749756)
41. The Effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6.
Seto WK; Tanaka Y; Liu K; Lai CL; Yuen MF
Am J Gastroenterol; 2011 May; 106(5):1007-8. PubMed ID: 21540909
[No Abstract] [Full Text] [Related]
42. IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population.
Dong ZX; Zhou HJ; Xiang XG; Guo SM; Zhuang Y; Zhao GD; Xie Q
J Dig Dis; 2015 Feb; 16(2):90-7. PubMed ID: 25312023
[TBL] [Abstract][Full Text] [Related]
43. A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy.
Yuan H; Adams-Huet B; Petersen T; Attar N; Lee WM; Jain MK
J Med Virol; 2012 Dec; 84(12):1913-9. PubMed ID: 23080496
[TBL] [Abstract][Full Text] [Related]
44. Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy.
Shaker OG; Sadik NA
J Gastroenterol Hepatol; 2012 Dec; 27(12):1842-9. PubMed ID: 23020144
[TBL] [Abstract][Full Text] [Related]
45. Early viral kinetics during hepatitis C virus genotype 6 treatment according to IL28B polymorphisms.
Akkarathamrongsin S; Payungporn S; Thong VD; Poovorawan K; Prapunwattana P; Poovorawan Y; Tangkijvanich P
World J Gastroenterol; 2014 Aug; 20(30):10599-605. PubMed ID: 25132781
[TBL] [Abstract][Full Text] [Related]
46. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
[TBL] [Abstract][Full Text] [Related]
47. Impact of IL-28B SNPs on control of hepatitis C virus infection: a genome-wide association study.
Imazeki F; Yokosuka O; Omata M
Expert Rev Anti Infect Ther; 2010 May; 8(5):497-9. PubMed ID: 20455677
[No Abstract] [Full Text] [Related]
48. Clinical utility of interleukin-28B testing in patients with genotype 1.
Lai M; Afdhal NH
Hepatology; 2012 Jul; 56(1):367-72. PubMed ID: 22511388
[No Abstract] [Full Text] [Related]
49. Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.
Kim SR; El-Shamy A; Imoto S; Kim KI; Ide YH; Deng L; Shoji I; Tanaka Y; Hasegawa Y; Ota M; Hotta H
J Gastroenterol; 2012 Oct; 47(10):1143-51. PubMed ID: 22441534
[TBL] [Abstract][Full Text] [Related]
50. IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis.
Zheng H; Li M; Chi B; Wu XX; Wang J; Liu DW
Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):576-83. PubMed ID: 25769643
[TBL] [Abstract][Full Text] [Related]
51. [IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].
Pár A; Pár G; Tornai I; Szalay F; Várszegi D; Fráter E; Papp M; Lengyel G; Fehér J; Varga M; Gervain J; Schuller J; Nemes Z; Péterfi Z; Tusnádi A; Hunyady B; Haragh A; Szinku Z; Pálinkás L; Berki T; Vincze A; Kisfali P; Melegh B
Orv Hetil; 2013 Aug; 154(32):1261-8. PubMed ID: 23916907
[TBL] [Abstract][Full Text] [Related]
52. Role of IL28B for chronic hepatitis C treatment toward personalized medicine.
Matsuura K; Watanabe T; Tanaka Y
J Gastroenterol Hepatol; 2014 Feb; 29(2):241-9. PubMed ID: 24325405
[TBL] [Abstract][Full Text] [Related]
53. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.
Ogawa E; Furusyo N; Murata M; Ikezaki H; Ihara T; Hayashi T; Toyoda K; Taniai H; Okada K; Kainuma M; Hayashi J
J Hepatol; 2012 Sep; 57(3):534-40. PubMed ID: 22613000
[TBL] [Abstract][Full Text] [Related]
54. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.
Kawaoka T; Takahashi S; Takaki S; Hiramatsu A; Waki K; Hiraga N; Miki D; Tsuge M; Imamura M; Kawakami Y; Aikata H; Ochi H; Onoe T; Tashiro H; Ohdan H; Chayama K
J Gastroenterol Hepatol; 2012 Sep; 27(9):1467-72. PubMed ID: 22432893
[TBL] [Abstract][Full Text] [Related]
55. Influence of genes suppressing interferon effects in peripheral blood mononuclear cells during triple antiviral therapy for chronic hepatitis C.
Iijima S; Matsuura K; Watanabe T; Onomoto K; Fujita T; Ito K; Iio E; Miyaki T; Fujiwara K; Shinkai N; Kusakabe A; Endo M; Nojiri S; Joh T; Tanaka Y
PLoS One; 2015; 10(2):e0118000. PubMed ID: 25706116
[TBL] [Abstract][Full Text] [Related]
56. [Not Available].
Kucherenko A; Pampukha V; Romanchuk K; Chernushyn S; Bobrova I; Moroz L; Livshits L
Tsitol Genet; 2016; 50(5):79-84. PubMed ID: 30480920
[TBL] [Abstract][Full Text] [Related]
57. [PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C].
Ogurtsov PP; Kukhareva EI
Klin Med (Mosk); 2016; 94(3):224-30. PubMed ID: 27522730
[TBL] [Abstract][Full Text] [Related]
58. Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study.
Shimada N; Toyoda H; Tsubota A; Ide T; Takaguchi K; Kato K; Kondoh M; Matsuyama K; Kumada T; Sata M
J Gastroenterol; 2014 Nov; 49(11):1485-94. PubMed ID: 24287582
[TBL] [Abstract][Full Text] [Related]
59. Infectious disease. Despite setbacks, optimism on drugs for hepatitis C.
Cohen J
Science; 2012 Sep; 337(6101):1450-1. PubMed ID: 22997303
[No Abstract] [Full Text] [Related]
60. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.
Hsu CS; Hsu SJ; Chen HC; Tseng TC; Liu CH; Niu WF; Jeng J; Liu CJ; Lai MY; Chen PJ; Kao JH; Chen DS
Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3719-24. PubMed ID: 21321200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
